MA-BOARD-INTERNATIONAL
Board International, the all-in-one Board Decision-Making Platform vendor, today announced strong Q2 2021 performance, achieving a 45% increase in ARR across the last 12 months.
The company experienced robust levels of growth in Q2 2021, which included a 58% increase in new Software ARR orders compared to the same quarter last year, contributing to a 69% increase in H1 2021. Board has more than 3,000 customers worldwide and welcomed 54 new brands in Q2 2021, including Jhpiego, Zentiva, Evergreen Environmental, and Luye Pharma. Additionally, Board registered a Net Retention Rate of 114%.
During the second quarter of the year, Board announced the addition of Marco Limena to its Board of Directors as Non-Executive Director and Senior Advisor. The company has also hired more than 125 people since the beginning of the year, growing its employee base by 15% to reach a total headcount of 500 employees across 25 countries. These new hires include various industry leaders and experts, including Mr. Christof Majer as Global VP of Alliances & Channel, who will lead partner business strategy, and Mr. Marcel Doppenberg as Sales Director for the Benelux Region, who will drive local growth.
On April 28, Board released Board Spring 21, the latest version of its market-leading Decision-Making Platform. The new version represents a great milestone in the evolution of Board’s technology and empowers organizations to access supercharged performance, unmatched flexibility, rock-solid reliability, and a seamless upgrade path from previous versions. Board continues to replace legacy applications and spreadsheets, driving a new era of decision-making, helping enterprises succeed in a constantly changing reality through greater planning agility and more accurate insights.
During the second quarter, Board also continued to strengthen its position as a leading provider of unified Business Intelligence, Planning, and Predictive Analytics, and its value proposition received significant attention from analysts. Board International was recognized as a March 2021 Gartner Peer Insights Customers’ Choice for Cloud Financial Planning and Analysis (FP&A) Solutions, confirmed as a Market Leader with the Best Portfolio Capabilities in Integrated Planning & Analytics by BARC, and named a Leader in the Customer Experience and Vendor Credibility models in Dresner Advisory’s 2021 Wisdom of Crowds Market Study for both BI and EPM.
"I am very proud of these results, for which I want to congratulate the entire Board team. Our flexible, all-in-one Decision-Making Platform gives organizations a strong competitive advantage. It is the perfect choice for functional planning requirements and also for achieving the ideal state of unifying planning across the enterprise," comments Maurizio Carli, CEO of Board International. "In the second half of the year, we will continue focusing on product innovation to enhance our customer experience and support growing market demand."
About Board
Board is the #1 Decision-Making Platform. Founded in 1994, Board International enables people to have a transformative impact on their business, helping them to intuitively leverage their data in a flexible, all-in-one environment. By unifying Business Intelligence, Planning, and Predictive Analytics, the Board platform allows companies to produce a single, accurate, and complete view of business information, gain actionable insights, and achieve full control of performance across the entire organization. Thanks to Board, global enterprises such as M&S, Coca-Cola, Ricoh, KPMG, Puma, Siemens, and ZF Group have deployed end-to end decision-making applications at a fraction of the time and cost associated with traditional solutions. www.board.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210720005826/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 04:37:00 CET | Press release
The Challenge: Deepfakes undermine both the accuracy and fairness of AI face detection due to variations in human features.The Technology: Ant International’s AI model uses a novel ‘Mixture of Experts’-based Adversarial Debiasing approach to achieve superior fairness and accuracy across diverse demographics.The Impact: This advancement strengthens payment security, offering robust protection against deepfake fraud and enhancing eKYC compliance globally. Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the Nati
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
